LIC frequency in sorted fractions of AML
| AML . | Fraction . | Dose . | LIC frequency (95% confidence interval) . | LICs per 106 MNCs . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 cells . | 103 cells . | 104 cells . | 2 × 104 cells . | 5 × 104 cells . | 105 cells . | 5 × 105 cells . | 106 cells . | 3 × 106 cells . | ||||
| 3 | CD34−CD38− | 2/4 | 3/4 | 3/3 | 3/3 | 3/3 | 1 in 458 (153-1369) | 432 | ||||
| 3 | CD34−CD38+ | 0/4 | 3/4 | 4/4 | 3/3 | 3/3 | 1 in 873 (275-2768) | 918 | ||||
| 9 | CD34−CD38− | 0/3 | 4/4 | 4/4 | 1 in 245 454 (85 866-701 648) | 2.2 | ||||||
| 9 | CD34−CD38+ | 0/4 | 2/5 | 2/2 | 3/3 | 1 in 231 326 (83 726-639 131) | 1.8 | |||||
| 17 | CD34−CD38− | 0/1 | 1/3 | 4/4 | 4/4 | 4/4 | 4/4 | 1 in 2164 (538-8698) | 228 | |||
| 17 | CD34−CD38+ | 1/3 | 3/4 | 4/4 | 3/3 | 1 in 58 407 (19 219-177 497) | 8.5 | |||||
| 17 | CD34+CD38− | 2/3 | 6/8 | 1 in 540 (236-1235) | 11 | |||||||
| 17 | CD34+CD38+ | 3/5 | 2/2 | 1 in 1091 (339-3506) | 2.3 | |||||||
| 25 | CD34− | 0/1 | 0/2 | 0/3 | 2/2 | 1 in 3 327 588 (885 486-12 504 816) | 0.1 | |||||
| 25 | CD34+ | 0/3 | 1/2 | 2/3 | 2/2 | 1 in 878 831 (321 224-2 404 374) | 0.7 | |||||
| AML . | Fraction . | Dose . | LIC frequency (95% confidence interval) . | LICs per 106 MNCs . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 102 cells . | 103 cells . | 104 cells . | 2 × 104 cells . | 5 × 104 cells . | 105 cells . | 5 × 105 cells . | 106 cells . | 3 × 106 cells . | ||||
| 3 | CD34−CD38− | 2/4 | 3/4 | 3/3 | 3/3 | 3/3 | 1 in 458 (153-1369) | 432 | ||||
| 3 | CD34−CD38+ | 0/4 | 3/4 | 4/4 | 3/3 | 3/3 | 1 in 873 (275-2768) | 918 | ||||
| 9 | CD34−CD38− | 0/3 | 4/4 | 4/4 | 1 in 245 454 (85 866-701 648) | 2.2 | ||||||
| 9 | CD34−CD38+ | 0/4 | 2/5 | 2/2 | 3/3 | 1 in 231 326 (83 726-639 131) | 1.8 | |||||
| 17 | CD34−CD38− | 0/1 | 1/3 | 4/4 | 4/4 | 4/4 | 4/4 | 1 in 2164 (538-8698) | 228 | |||
| 17 | CD34−CD38+ | 1/3 | 3/4 | 4/4 | 3/3 | 1 in 58 407 (19 219-177 497) | 8.5 | |||||
| 17 | CD34+CD38− | 2/3 | 6/8 | 1 in 540 (236-1235) | 11 | |||||||
| 17 | CD34+CD38+ | 3/5 | 2/2 | 1 in 1091 (339-3506) | 2.3 | |||||||
| 25 | CD34− | 0/1 | 0/2 | 0/3 | 2/2 | 1 in 3 327 588 (885 486-12 504 816) | 0.1 | |||||
| 25 | CD34+ | 0/3 | 1/2 | 2/3 | 2/2 | 1 in 878 831 (321 224-2 404 374) | 0.7 | |||||
NOD/SCID/IL2rγ−/− mice were used as hosts for samples 3 and 9. NOD/SCID/β2m−/− mice were used as hosts for samples 17 and 25. Mice were sacrificed at 10 weeks for sample 25, 12 weeks for samples 3 and 17, and 15 weeks for sample 9.
Data are reported as number of mice with AML/number of mice receiving transplant.